Participant flow

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations · Source last updated 2016-09-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   First-line patients were enrolled after Amendment 1 with a starting oral dose of Afatinib 40 mg daily after Amendment 2. Dose reduction scheme was defined for patients unable to tolerate this dose.

   id

   FG000

   title

   First-line Afatinib 40 mg

2. description

   First-line patients were enrolled after Amendment 1 with a starting oral dose of Afatinib 50 mg daily. Dose reduction scheme was defined for patients unable to tolerate this dose.

   id

   FG001

   title

   First-line Afatinib 50 mg

3. description

   Second-line patients received a starting oral dose of Afatinib 40 mg daily only after Amendment 2. Dose reduction scheme was defined for patients unable to tolerate this dose.

   id

   FG002

   title

   Second-line Afatinib 40 mg

4. description

   Second-line patients received a starting oral dose of Afatinib 50 mg daily. Dose reduction scheme was defined for patients unable to tolerate this dose.

   id

   FG003

   title

   Second-line Afatinib 50 mg

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         5

      3. group Id

         FG002

         num Subjects

         1

      4. group Id

         FG003

         num Subjects

         8

      type

      Other Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         18

      2. group Id

         FG001

         num Subjects

         30

      3. group Id

         FG002

         num Subjects

         6

      4. group Id

         FG003

         num Subjects

         49

      type

      Progressive disease

   3. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         2

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         1

      type

      Refused continuation of study medication

   4. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         3

      type

      Other than stated

   milestones

   1. achievements

      1. comment

         entered and treated

         group Id

         FG000

         num Subjects

         23

      2. comment

         entered and treated

         group Id

         FG001

         num Subjects

         38

      3. comment

         entered and treated

         group Id

         FG002

         num Subjects

         7

      4. comment

         entered and treated

         group Id

         FG003

         num Subjects

         61

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         23

      2. group Id

         FG001

         num Subjects

         38

      3. group Id

         FG002

         num Subjects

         7

      4. group Id

         FG003

         num Subjects

         61

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice